Payment overview · 2025
General Payments
$1,026.15
65 reported records · 14 companies
Healthcare provider profile · identity verified
Scott C Layne, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · FLOWOOD, MS · NPI 1922106749
Verified facts
What the public records show
CMS Open Payments records show Scott C Layne, M.D. received $1,026.15 in general payments during 2025 across 65 reported records.
PFIZER INC. accounted for 27.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Linzess, Mounjaro, Ozempic, Synthroid, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 145 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 318 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $284.83 | 27.8% | 14 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $192.18 | 18.7% | 14 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $149.72 | 14.6% | 10 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $142.16 | 13.8% | 13 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $53.65 | 5.2% | 3 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $52.70 | 5.1% | 2 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $32.63 | 3.2% | 2 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $24.79 | 2.4% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.91 | 2.0% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $18.99 | 1.9% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $18.36 | 1.8% | 1 | 2025 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | Unresolved — no canonical attribution shown | $16.17 | 1.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.40 | 1.5% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $3.66 | 0.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,026.15 | 65 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $194.73 | 8 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $194.73 | 8 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $194.73 | 8 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $176.50 | 12 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $176.50 | 12 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $124.03 | 7 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $104.73 | 7 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $90.10 | 6 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $90.10 | 6 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $59.11 | 4 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $38.62 | 2 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $38.47 | 2 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $32.63 | 2 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $20.91 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $18.99 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $18.99 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $18.36 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $18.13 | 6 | 2025 |
Source payment records
|
|||||
| BOOSTRIX Normalized: boostrix |
Biological | GlaxoSmithKline, LLC. | $18.13 | 6 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $18.13 | 6 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka Pharmaceutical Development & Commercialization, Inc. | $16.17 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $15.40 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.03 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.03 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $13.90 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $11.12 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $3.66 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 318 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 49 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 71 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 67 | exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 145 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
49 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
145 | 31 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
91 | 24 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
91 | 24 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
71 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
67 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
318 | 58 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
27 | 27 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 884 | 240 |
| Amlodipine Besylate | Amlodipine Besylate | 725 | 183 |
| Atorvastatin Calcium | Atorvastatin Calcium | 575 | 152 |
| Levothyroxine Sodium | Levothyroxine Sodium | 528 | 129 |
| Metoprolol Succinate | Metoprolol Succinate | 429 | 124 |
| Gabapentin | Gabapentin | 424 | 111 |
| Omeprazole | Omeprazole | 422 | 117 |
| Trazodone Hcl | Trazodone Hcl | 347 | 81 |
| Eliquis | Apixaban | 318 | 58 |
| Pantoprazole Sodium | Pantoprazole Sodium | 302 | 96 |
| Famotidine | Famotidine | 283 | 85 |
| Metformin Hcl | Metformin Hcl | 283 | 84 |
| Meloxicam | Meloxicam | 244 | 78 |
| Tamsulosin Hcl | Tamsulosin Hcl | 243 | 66 |
| Losartan Potassium | Losartan Potassium | 237 | 73 |
| Sertraline Hcl | Sertraline Hcl | 237 | 59 |
| Furosemide | Furosemide | 224 | 70 |
| Zolpidem Tartrate | Zolpidem Tartrate | 223 | 39 |
| Duloxetine Hcl | Duloxetine Hcl | 213 | 50 |
| Lisinopril | Lisinopril | 213 | 62 |
| Clopidogrel | Clopidogrel Bisulfate | 209 | 54 |
| Hydrochlorothiazide | Hydrochlorothiazide | 200 | 62 |
| Montelukast Sodium | Montelukast Sodium | 198 | 46 |
| Valsartan | Valsartan | 193 | 54 |
| Ezetimibe | Ezetimibe | 189 | 62 |
| Potassium Chloride | Potassium Chloride | 177 | 51 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 176 | 40 |
| Carvedilol | Carvedilol | 165 | 45 |
| Escitalopram Oxalate | Escitalopram Oxalate | 149 | 34 |
| Synthroid | Levothyroxine Sodium | 145 | 31 |
| Fluticasone Propionate | Fluticasone Propionate | 140 | 60 |
| Tramadol Hcl | Tramadol Hcl | 137 | 35 |
| Alprazolam | Alprazolam | 133 | 32 |
| Donepezil Hcl | Donepezil Hcl | 124 | 32 |
| Simvastatin | Simvastatin | 121 | 32 |
| Allopurinol | Allopurinol | 120 | 30 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 120 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 116 | 28 |
| Pravastatin Sodium | Pravastatin Sodium | 116 | 32 |
| Memantine Hcl | Memantine Hcl | 115 | 25 |
| Lorazepam | Lorazepam | 104 | 18 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 103 | 31 |
| Metoprolol Tartrate | Metoprolol Tartrate | 100 | 28 |
| Spironolactone | Spironolactone | 100 | 29 |
| Tizanidine Hcl | Tizanidine Hcl | 100 | 38 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 97 | 29 |
| Mirtazapine | Mirtazapine | 95 | 19 |
| Irbesartan | Irbesartan | 93 | 25 |
| Jardiance | Empagliflozin | 91 | 24 |
| Fenofibrate | Fenofibrate | 88 | 29 |
| Citalopram Hbr | Citalopram Hydrobromide | 86 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 84 | 21 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 83 | 22 |
| Atenolol | Atenolol | 81 | 18 |
| Pioglitazone Hcl | Pioglitazone Hcl | 81 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 80 | 30 |
| Clonazepam | Clonazepam | 76 | 17 |
| Nebivolol Hcl | Nebivolol Hcl | 76 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 73 | 52 |
| Finasteride | Finasteride | 71 | 19 |
| Mounjaro | Tirzepatide | 71 | 12 |
| Glimepiride | Glimepiride | 70 | 25 |
| Ozempic | Semaglutide | 67 | 14 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 66 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 65 | 52 |
| Myrbetriq | Mirabegron | 63 | 11 |
| Clonidine Hcl | Clonidine Hcl | 62 | 13 |
| Oxybutynin Chloride | Oxybutynin Chloride | 60 | 15 |
| Warfarin Sodium | Warfarin Sodium | 60 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 59 | 16 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 59 | 18 |
| Ropinirole Hcl | Ropinirole Hcl | 58 | 12 |
| Azithromycin | Azithromycin | 57 | 45 |
| Januvia | Sitagliptin Phosphate | 57 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 57 | 11 |
| Bupropion Xl | Bupropion Hcl | 56 | 18 |
| Methylprednisolone | Methylprednisolone | 55 | 42 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 55 | 44 |
| Temazepam | Temazepam | 55 | suppressed |
| Xarelto | Rivaroxaban | 51 | 14 |
| Alendronate Sodium | Alendronate Sodium | 50 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 50 | 13 |
| Linzess | Linaclotide | 49 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 48 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 48 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 46 | 33 |
| Amiodarone Hcl | Amiodarone Hcl | 45 | 15 |
| Celecoxib | Celecoxib | 44 | 12 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 43 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 43 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 42 | 13 |
| Estradiol | Estradiol | 42 | 14 |
| Fluconazole | Fluconazole | 40 | 26 |
| Telmisartan | Telmisartan | 40 | 12 |
| Digoxin | Digoxin | 39 | suppressed |
| Ranolazine Er | Ranolazine | 39 | suppressed |
| Sucralfate | Sucralfate | 39 | 18 |
| Tresiba Flextouch U-100 | Insulin Degludec | 39 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 38 | 14 |
| Entresto | Sacubitril/Valsartan | 37 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 36 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 36 | 11 |
| Prednisone | Prednisone | 36 | 18 |
| Pregabalin | Pregabalin | 35 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 35 | suppressed |
| Dutasteride | Dutasteride | 34 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 34 | suppressed |
| Topiramate | Topiramate | 34 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 33 | 27 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 32 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 32 | suppressed |
| Lansoprazole | Lansoprazole | 31 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 31 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 30 | suppressed |
| Nifedipine Er | Nifedipine | 29 | suppressed |
| Nitroglycerin | Nitroglycerin | 29 | 19 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 29 | 17 |
| Primidone | Primidone | 28 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 28 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 27 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 27 | 27 |
| Divalproex Sodium Er | Divalproex Sodium | 26 | suppressed |
| Ketoconazole | Ketoconazole | 26 | 16 |
| Terazosin Hcl | Terazosin Hcl | 26 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 26 | 13 |
| Doxazosin Mesylate | Doxazosin Mesylate | 25 | suppressed |
| Lovastatin | Lovastatin | 25 | suppressed |
| Trulicity | Dulaglutide | 25 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 24 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 24 | suppressed |
| Levetiracetam | Levetiracetam | 23 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 23 | suppressed |
| Risperidone | Risperidone | 23 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 22 | suppressed |
| Aripiprazole | Aripiprazole | 22 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 22 | 14 |
| Dexlansoprazole Dr | Dexlansoprazole | 22 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 22 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 22 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 22 | suppressed |
| Baclofen | Baclofen | 21 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Diazepam | Diazepam | 20 | suppressed |
| Folic Acid | Folic Acid | 20 | suppressed |
| Naproxen | Naproxen | 20 | suppressed |
| Ramipril | Ramipril | 20 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 19 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 18 | suppressed |
| Hydrocortisone | Hydrocortisone | 18 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 17 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Latanoprost | Latanoprost | 17 | suppressed |
| Novolog Flexpen | Insulin Aspart | 17 | suppressed |
| Restasis | Cyclosporine | 17 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 17 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 16 | suppressed |
| Insulin Degludec Pen (U-100) | Insulin Degludec | 16 | suppressed |
| Nystatin | Nystatin | 16 | suppressed |
| Olanzapine | Olanzapine | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | 11 |
| Doxepin Hcl | Doxepin Hcl | 15 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 15 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 15 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 15 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 14 | suppressed |
| Levemir Flexpen | Insulin Detemir | 14 | suppressed |
| Methocarbamol | Methocarbamol | 14 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 14 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 14 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 14 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | 11 |
| Mupirocin | Mupirocin | 13 | 11 |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Repatha Sureclick | Evolocumab | 13 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Cephalexin | Cephalexin | 12 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 12 | suppressed |
| Nateglinide | Nateglinide | 12 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 12 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 12 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 11 | suppressed |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Carbamazepine Er | Carbamazepine | 11 | suppressed |
| Celebrex | Celecoxib | 11 | suppressed |
| Clomipramine Hcl | Clomipramine Hcl | 11 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 11 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,026.15 · 65 records | PFIZER INC. | ABRYSVO, AREXVY, BOOSTRIX, CAPVAXIVE, COMIRNATY, ELIQUIS, GARDASIL 9, KISUNLA, LINZESS, MOUNJARO, NEXLETOL, NURTEC ODT, OFEV, Ozempic, PREVNAR 20, QULIPTA, REXULTI, Rybelsus, SHINGRIX, SYNTHROID, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, VRAYLAR, WATCHMAN Access System, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error